Clinical Trial Search

Primary: Kaposi Sarcoma (KS) Status at Week 48 Compared to Study Entry — 43; 47; 13; 9 Participants — p=0.911

Primary: Maximum Tolerated Dose of Lenalidomide Defined as the Dose Level at Which 0/6 or 1/6 Subjects Experience Dose Limiting Toxicity (DLT) With the Next Higher Dose Having at…

Primary: Response Rate — 31 Percentage of participants

Primary: Number of Participants With Complete Response — 1; 3 participants

Primary: Overall Response Rate (ORR) of Six Cycles of Liposomal Doxorubicin Combined With Bevacizumab in Patients With Advanced KS. — 50; 67 percentage of participants

Primary: Total Score on Quality of Life Assessed Using Functional Assessment of Cancer Therapy-General (FACT-G) Questionnaire — 56.9 score on a scale

Primary: Preliminary Assessment of the Temperature of Kaposi's Sarcoma Lesions Compared to the Temperature in the Normal Skin Measured With Thermography — 1.1 Celsius

Primary: Number of Participants With a Decrease in Kaposi's Sarcoma (KS) Total Surface Area — 11 Participants

Primary: Proportion of Patients Who Achieve a Clinical Response — 0.33 proportion

Primary: Number of Participants With Grades 1-4 Adverse Events That Are Possibly, Probably, and/or Definitely Attributed to Pomalidomide — 21; 10; 1; 0 Participants

Primary: Overall Response Rate — 0.577 proportion of participants

Primary: Number of Participants Who Died of Immune Reconstitution Inflammatory Syndrome Associated to Kaposi Sarcoma (IRIS-KS) — 0; 3 Participants

Primary: Tumor Response Rate Every 4 Weeks — 4; 1 participants

Primary: Objective Response Rate — 0; 7; 6 Participants

Primary: Proportion of Participants Experiencing Clinical Response — 56.5 percentage of participants

Primary: Efficacy of Therapeutic Escalation of Standard Dose Nelfinavir, Followed by High Dose Nelfinavir, for Treatment of Kaposi Sarcoma Lesions for HIV Positive Participants…

Primary: To Determine the Safety of Escalating Doses of Tc 99m Tilmanocept in HIV Subjects With Biopsy-confirmed KS. — 0; 0; 0 Safety Signals

Primary: Cumulative Rate of Progression-Free Survival by Week 48 for ET+ART vs. PTX+ART — 19.7; 49.8 Cumulative events per 100 persons

Primary: Percentage of Participants With an Overall Clinical Benefit Response — 63; 100; 50; 67 percentage of participants

Primary: Number of Patients Alive at 2 Years Without Recurrent Brain Lymphoma or Severe Neurocognitive Defects — 8 Participants

Primary: Localization — 5 participants

Primary: Complete Response Rate (Complete Response and Complete Response Unconfirmed) Defined as Disappearance of All Evidence of Disease Based on Radiographic Findings on CT or…

Primary: Percentage of Participants Achieving Complete Response in 5-FU Arm and Observation Arm Using ITT Population — 5; 9 Participants — p=0.1877

Primary: Proportion of Patients With Regression of Perianal High-grade Squamous Intraepithelial Lesions (HSIL) — 0.515 proportion of participants

Primary: Mortality Rate — 0.68; 0.31 deaths per person-year

Primary: Estimates of Site-specific Incident Cases and Site-specific Prevalence of Cases Presenting With Human Immunodeficiency Virus (HIV) and Cancer Presenting Over 9 Months at…

Primary: Survival — 6; 7; 3; 20 participants

Primary: Efficacy of Nonmyeloablative Preparative Regimen — 4 Participants

Primary: Number of Grade 2 or Greater AEs — 10; 2 Participants — p=0.07

Primary: Anal Cancer Incidence — 173; 402 cases per 100,000 person years